{
    "root": "30b771ad-2a9b-a5be-e063-6294a90a6bdf",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "IMVEXXY",
    "value": "20250319",
    "ingredients": [
        {
            "name": "MEDIUM-CHAIN TRIGLYCERIDES",
            "code": "C9H2L21V7U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13959"
        },
        {
            "name": "PEG-6 STEARATE",
            "code": "8LQC57C6B0",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11225"
        },
        {
            "name": "PEG-32 STEARATE",
            "code": "33GX5WQC0M",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11225"
        },
        {
            "name": "GLYCOL STEARATE",
            "code": "0324G66D0E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01638"
        },
        {
            "name": "SORBITAN",
            "code": "6O92ICV9RU",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14474"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "ETHYL ACETATE",
            "code": "76845O8NMZ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27750"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYVINYL ACETATE PHTHALATE",
            "code": "58QVG85GW3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30089"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_61995"
        },
        {
            "name": "ESTRADIOL",
            "code": "4TI98Z838E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_23965"
        }
    ],
    "indications": {
        "text": "imvexxy estrogen indicated treatment moderate severe dyspareunia , symptom vulvar vaginal atrophy , due menopause ( 1 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "generally , estrogen prescribed postmenopausal woman uterus , consider addition progestogen reduce risk endometrial cancer . generally , woman without uterus need progestogen addition estrogen therapy . cases , however , hysterectomized women history endometriosis may need progestogen [ ( 5.3 , 5.15 ) ] . estrogen-alone , combination progestogen , lowest effective dose shortest duration consistent treatment goals risks individual woman . re-evaluate postmenopausal women periodically clinically appropriate determine treatment still necessary .",
        "doid_entities": [
            {
                "text": "endometrial cancer (DOID:1380)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1380"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "endometriosis (DOID:289)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_289"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "imvexxy contraindicated women following conditions : undiagnosed abnormal genital bleeding [ warning ( 5.3 ) ] . breast cancer history breast cancer [ ( 5.3 ) ] . estrogen-dependent neoplasia [ ( 5.3 ) ] . active dvt , pe , history conditions [ ( 5.2 ) ] . active arterial thromboembolic disease ( example , stroke myocardial infarction ) , history conditions [ ( 5.2 ) ] . known anaphylactic reaction , angioedema , hypersensitivity imvexxy . hepatic impairment disease . protein c , protein , antithrombin deficiency , known thrombophilic disorders .",
    "indications_original": "IMVEXXY is an estrogen indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause ( 1 ).",
    "contraindications_original": "Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, consider addition of a progestogen to reduce the risk of endometrial cancer.\n                  Generally, a woman without a uterus does not need to use a progestogen in addition to her estrogen therapy. In some cases, however, hysterectomized women with a history of endometriosis may need a progestogen\n \n  [see\n  \n   Warnings and Precautions (5.3,\n  \n   5.15)]\n \n  .\n\n \n                  Use estrogen-alone, or in combination with a progestogen, at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Re-evaluate postmenopausal women periodically as clinically appropriate to determine if treatment is still necessary.",
    "adverseReactions_original": "IMVEXXY is contraindicated in women with any of the following conditions:\n                  \n                     Undiagnosed abnormal genital bleeding\n  \n   [see\n   \n    Warning and Precautions (5.3)].\n  \n   \n                     \n                     Breast cancer or a history of breast cancer\n  \n   [see\n   \n    Warnings and Precautions (5.3)].\n  \n   \n                     \n                     Estrogen-dependent neoplasia\n  \n   [see\n   \n    Warnings and Precautions (5.3)].\n  \n   \n                     \n                     Active DVT, PE, or history of these conditions\n  \n   [see\n   \n    Warnings and Precautions (5.2)].\n  \n   \n                     \n                     Active arterial thromboembolic disease (for example, stroke or MI), or a history of these conditions\n  \n   [see\n   \n    Warnings and Precautions (5.2)].\n  \n   \n                     \n                     Known anaphylactic reaction, angioedema, or hypersensitivity to IMVEXXY.\n                     Hepatic impairment or disease.\n                     Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders.",
    "drug": [
        {
            "name": "IMVEXXY",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13959"
        }
    ]
}